Trial Profile
ITT-PMS Extension An extension study of intrathecal therapy with monoclonal antibodies in progressive multiple sclerosis
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 24 Sep 2018
Price :
$35
*
At a glance
- Drugs Rituximab (Primary)
- Indications Multiple sclerosis
- Focus Therapeutic Use
- Acronyms ITT-PMS Ext
- 19 Sep 2018 Status changed from recruiting to completed.
- 25 Nov 2016 New trial record